Offene Studien adjuvant

Adjuvant Dynamic marker-Adjusted Personalized Therapy comparing endocrine therapy plus ribociclib versus chemotherapy in intermediate risk HR+/HER2- early breast cancer (ADAPTcycle)

A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of adjuvant Giredestrant compared with Physician's Choice of Adjuvant Endocrine Monotherapy in patients with Estrogen Receptor−Positive, HER2-Negative Early Breast Cancer

Phase III postneoadjuvant study evaluating Sacituzumab Govitecan, an Antibody Drug Conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment